Jornay Pm is an attention deficit hyperactivity disorder (ADHD) treatment drug owned by Ironshore Pharms. The active ingredient in Jornay Pm is methylphenidate hydrochloride and it was authorized for market use on August 8, 2018.
The release of a generic version of Jornay Pm is likely after March 23, 2032. This is due to the expiry of the last patent held by Ironshore Pharms.
Jornay Pm is used for the treatment of attention deficit hyperactivity disorder (ADHD). Its active ingredient, methylphenidate hydrochloride, helps increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.
Jornay Pm, an ADHD treatment drug, has a total of 15 patents, all of which expire on March 23, 2032. That’s when Jornay Pm generic could be available. Below are the details of the patent: